Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin; S. Marktel; M. Bua; R. M. Szydlo; A. Franceschino; I. Nathan; I. Foot; C. Crawley; T. Nakorn Nakorn; E. Olavarria; A. Lennard; A. Neylon; S. G. O'Brien; J. M. Goldman; J. F. Apperley

doi:10.1038/sj.leu.2402996

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin, S. Marktel, M. Bua, R. M. Szydlo, A. Franceschino, I. Nathan, I. Foot, C. Crawley, T. Nakorn Nakorn, E. Olavarria, A. Lennard, A. Neylon, S. G. O'Brien, J. M. Goldman, J. F. Apperley

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.

Original language	English
Pages (from-to)	1448-1453
Number of pages	6
Journal	Leukemia
Volume	17
Issue number	8
DOIs	https://doi.org/10.1038/sj.leu.2402996
State	Published - 1 Aug 2003
Externally published	Yes

Keywords

Chronic myeloid leukaemia
Cytogenetic response
Imatinib mesylate
Neutropenia
Prognostic factors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.leu.2402996

Cite this

Marin, D., Marktel, S., Bua, M., Szydlo, R. M., Franceschino, A., Nathan, I., Foot, I., Crawley, C., Nakorn, T. N., Olavarria, E., Lennard, A., Neylon, A., O'Brien, S. G., Goldman, J. M., & Apperley, J. F. (2003). Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia, 17(8), 1448-1453. https://doi.org/10.1038/sj.leu.2402996

@article{942e3b683e444e24bdb0bc5ddd35dedd,

title = "Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa",

abstract = "We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.",

keywords = "Chronic myeloid leukaemia, Cytogenetic response, Imatinib mesylate, Neutropenia, Prognostic factors",

author = "D. Marin and S. Marktel and M. Bua and Szydlo, {R. M.} and A. Franceschino and I. Nathan and I. Foot and C. Crawley and Nakorn, {T. Nakorn} and E. Olavarria and A. Lennard and A. Neylon and O'Brien, {S. G.} and Goldman, {J. M.} and Apperley, {J. F.}",

note = "Funding Information: help and supply of Glivec. This study was supported in part by the Leukaemia Research Fund.",

year = "2003",

month = aug,

day = "1",

doi = "10.1038/sj.leu.2402996",

language = "English",

volume = "17",

pages = "1448--1453",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

Marin, D, Marktel, S, Bua, M, Szydlo, RM, Franceschino, A, Nathan, I, Foot, I, Crawley, C, Nakorn, TN, Olavarria, E, Lennard, A, Neylon, A, O'Brien, SG, Goldman, JM & Apperley, JF 2003, 'Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa', Leukemia, vol. 17, no. 8, pp. 1448-1453. https://doi.org/10.1038/sj.leu.2402996

TY - JOUR

T1 - Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

AU - Marin, D.

AU - Marktel, S.

AU - Bua, M.

AU - Szydlo, R. M.

AU - Franceschino, A.

AU - Nathan, I.

AU - Foot, I.

AU - Crawley, C.

AU - Nakorn, T. Nakorn

AU - Olavarria, E.

AU - Lennard, A.

AU - Neylon, A.

AU - O'Brien, S. G.

AU - Goldman, J. M.

AU - Apperley, J. F.

N1 - Funding Information: help and supply of Glivec. This study was supported in part by the Leukaemia Research Fund.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.

AB - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.

KW - Chronic myeloid leukaemia

KW - Cytogenetic response

KW - Imatinib mesylate

KW - Neutropenia

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0042528659&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402996

DO - 10.1038/sj.leu.2402996

M3 - Article

AN - SCOPUS:0042528659

VL - 17

SP - 1448

EP - 1453

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this